32 results about "Myelofibrosis" patented technology

In part, the disclosure relates to methods of treating myeloproliferative disorders by administering one or more Serum Amyloid Protein (SAP) proteins. In certain aspects, the method further comprisesmonitoring treatment efficacy by measuring change in mutant allele burden. In certain aspects, the disclosure relates to methods of treating myelofibrosis in patient sub-populations who carry myelofibrosis-associated mutations in some of their cells by administering an SAP protein.

The invention discloses a medicine composition for treating chronic aplastic anemia. The medicine composition is prepared by the following main pharmacophore raw materials in parts by weight: 100-200 of thalattosaurus, 50-150 of herba epimedii, 250-400 of radix pseudostellariae, 150-250 of rehmannia, 250-350 of caulis spatholobi, and 150-250 of coloured malt. A preparation method comprises the following steps of: weighing the pharmacophore raw materials according to the formula; and uniformly mixing the pharmacophore raw materials through grinding, water extraction and concentration, or a manner of combining grinding and water extraction and concentration, thereby obtaining the end product. The medicine composition can be used for invigorating the kidney, supplying vital essence and marrow, and hematogenesis, is good for symptoms of various deficiency of essence and blood such as the deficiency of the kidney essence, marrow deficiency and blood disorders, and is used for treating aplastic anemia, myelodysplasia syndrome, leukemia, paroxysmal nocturnal hemoglobinuria, myelofibrosis, and patients with the symptoms caused by chemotherapy and the like.

The present invention relates to pharmaceutical compositions comprising heterocyclic diamidines and their use in the prophylaxis and / or treatment of diseases associated with fibrosis, in particular for the treatment of diseases such as systemic sclerosis (limited cutaneous scleroderma and diffuse cutaneous scleroderma), pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, chronic graft-versus-host disease, Crohn's disease, arthrofibrosis, myelofibrosis, Dupuytren's disease and nephrogenic systemic fibrosis and tumours selected from mamma carcinoma, endometrial adenocarcinoma, ovarian serous tumor, lung adenocarcinoma, lung squamous cell tumor, colorectal tumor and pancreatic tumor.

The present invention relates to a pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and / or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative of the invention is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like. The pyrrolopyrimidine five-membered azacyclic derivative has the general formula of formula I

In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents.

The invention provides a use of chlorogenic acid in preparing medicament for treating marrow fibrillation and also provides a pharmaceutical composition containing the chlorogenic acid as the active constituent.

The invention discloses a medicine composition for curing myelofibrosis and hepatofibrosis and a preparation method of the medicine composition. The main raw materials of the medicine composition include, by weight, 200-300 of vinegar turtles, 300-400 of fried peach seeds, 50-150 of cooked rhubarb, 100-200 of common burreed rhizome, 300-400 of leeches, 100-200 of rehmannia roots, 10-110 of human placenta, 10-110 of panax notoginseng and 50-150 of liquorice. The preparation method comprises steps of weighing the raw materials in accordance with the above prescription, uniformly mixing the raw materials through smashing and water-extraction concentration or a combination method of the smashing and the water-extraction concentration and obtaining the medicine composition. The medicine composition can soften hard lumps and dispel nodes, removes blood stasis for promoting tissue regeneration and nourishes blood and can be used for curing syndromes such as accumulation lumps under the rib side, sallowness, weakness, palpitation, shortness of breath, primary myelofibrosis, liver cirrhosis, hepatosplenomegaly and anemia which are caused by blood stasis and non-generation of new blood.